Farydak
Generic name: Panobinostat
Drug class:
Histone deacetylase inhibitors
Usage of Farydak
Farydak is a cancer medicine that interferes with the growth and spread of cancer cells in the body.
Farydak is used in combination with other drugs to treat multiple myeloma in adults who have received at least two other types of treatment.
Farydak was approved by the US Food and Drug Administration (FDA) on an "accelerated" basis. In clinical studies, the medicine slowed progression of the disease. However, it has not been shown that Farydak can improve symptoms or lengthen survival time.
Farydak side effects
Get emergency medical help if you have signs of an allergic Reaction to Farydak: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Farydak can cause serious or fatal heart problems. Get medical attention if you have:
Call your doctor at once if you have:
Common Farydak side effects may include:
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Before taking Farydak
Tell your doctor if you are sick with diarrhea, or if you've ever had:
Panobinostat can harm an unborn baby if the mother or the father is using this medicine.
You should not breastfeed while using this medicine.
Farydak is not approved for use by anyone younger than 18 years old.
Relate drugs
How to use Farydak
Usual Adult Dose of Farydak for Multiple Myeloma:
Initial dose: 20 mg orally once every other day for 3 doses per week (on Days 1, 3, 5, 8, 10, 12) in Weeks 1 and 2 of each 21-Day cycle for up to 8 cycles Duration of therapy: Up to 16 cycles (48 weeks) Comments: Consider continuing treatment of this drug for an additional 8 cycles (16 cycles total) for patients with clinical benefit who do not experience unresolved severe or medically significant toxicity. This drug is administered in combination with Bortezomib and Dexamethasone. Consult manufacturer product information for the recommended dosing for these two drugs. Use: Treatment of patients with multiple myeloma who have received at least 2 prior regimens, including bortezomib and an immunomodulatory agent
Warnings
Farydak can cause serious or fatal heart problems. Get medical attention if you have chest pain, fast or slow heartbeats, dizziness or fainting, swelling in your legs, blue lips, or shortness of breath.
Farydak can cause severe diarrhea. Call your doctor if you have severe diarrhea or stomach cramps, or if you get dehydrated (increased thirst, decreased urination, sweating or hot and dry skin).
Tell your doctor right away if you have any bleeding that will not stop, blood in your urine or stools, dizziness, confusion, vomiting or coughing up blood.
What other drugs will affect Farydak
Farydak can cause a serious heart problem. Your risk may be higher if you also use certain other medicines for infections, asthma, heart problems, high blood pressure, depression, mental illness, cancer, malaria, or HIV.
Other drugs may interact with panobinostat, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all your current medicines and any medicine you start or stop using.
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions